SCHEMBL364585

SCHEMBL364585

Nc1ccc(Oc2ccc(F)cc2)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.74
TDP1 Q9NUW8 3/20 0.74
CYP3A4 P08684 1/20 0.74
TSHR P16473 1/20 0.74
MAOA P21397 2/20 0.61
MEN1 O00255 4/20 0.59
KMT2A Q03164 4/20 0.59
KDM4E B2RXH2 1/20 0.59
MAPT P10636 5/20 0.58
MAOB P27338 3/20 0.58
TEAD4 Q15561 1/20 0.58
SMN1; SMN2 Q16637 3/20 0.56
GFER P55789 2/20 0.56
POLB P06746 1/20 0.56
MITF O75030 1/20 0.56
GAA P10253 1/20 0.56
NLRP1 Q9C000 1/20 0.56
NOD2 Q9HC29 1/20 0.56
SOS1 Q07889 1/20 0.54
NPC1 O15118 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL41849 0.86 ALDH1A1 (1.00) ALDH1A1TDP1CYP3A4TSHRMAOA
SCHEMBL2013073 0.86 ALDH1A1 (1.00) ALDH1A1TDP1CYP3A4TSHRMAOA
SCHEMBL202864 0.86 ALDH1A1 (1.00) ALDH1A1TDP1CYP3A4TSHRMAOA
SCHEMBL4446167 0.86 ALDH1A1 (1.00) ALDH1A1TDP1CYP3A4TSHRMAOA
SCHEMBL4455485 0.86 ALDH1A1 (1.00) ALDH1A1TDP1CYP3A4TSHRMAOA
SCHEMBL1331804 0.86 ALDH1A1 (1.00) ALDH1A1TDP1CYP3A4TSHRMAOA
SCHEMBL65211 0.86 ALDH1A1 (1.00) ALDH1A1TDP1CYP3A4TSHRMAOA
SCHEMBL10576066 0.86 ALDH1A1 (1.00) ALDH1A1TDP1CYP3A4TSHRMAOA
SCHEMBL6289867 0.86 SOS1 (0.58) ALDH1A1TDP1CYP3A4TSHRMEN1
SCHEMBL351854 0.86 SOS1 (0.58) ALDH1A1TDP1CYP3A4TSHRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 252 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116789574-B Preparation method and application of camphorsulfonamide compound containing diphenyl ether group 南京林业大学 2024-07-30 CN claimed
US-20050182050-A1 Therapeutic heterocyclic compounds ASTRAZENECA AB (SE) 2005-08-18 US claimed
US-6812225-B2 PYSCHOLOGICAL DISORDERS; ANTIDEPRESSANTS ASTRAZENECA AB (SE) 2004-11-02 US claimed
US-20030013708-A1 Therapeutic heterocyclic compounds ASTRAZENECA AB (SE) 2003-01-16 US claimed
US-12617795-B2 Substituted 6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidines, 5,7-dihydrofuro[3,4-d]pyrimidines, and pyrido[2,3-d]pyrimidines as KCC2 modulators ASTRAZENECA AB (SE) 2026-05-05 US disclosed
US-20260085064-A1 SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF KARYOPHARM THERAPEUTICS INC (US) 2026-03-26 US disclosed
CN-120424083-B Pyrrolo pyrimidine compound and preparation method and application thereof 江西省肿瘤医院(江西省第二人民医院、江西省癌症中心) 2026-02-27 CN disclosed
US-20250382273-A1 BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS INST NAT SANTE RECH MED (FR) 2025-12-18 US disclosed
US-12331040-B2 Substituted benzofuranyl and benzoxazolyl compounds and uses thereof Karyopharm Therapeutics Inc. (US) 2025-06-17 US disclosed
CN-119735594-A Fused pyrimidine compounds as KCC2 modulators 阿斯利康(瑞典)有限公司 2025-04-01 CN disclosed
CN-119707816-A Pyrazole hydrazide derivative containing diphenyl ether unit as well as preparation method and application thereof 江苏海洋大学 2025-03-28 CN disclosed
CN-119684300-A Fused pyrimidine compounds as KCC2 modulators 阿斯利康(瑞典)有限公司 2025-03-25 CN disclosed
US-6407099-B1 SUPPRESSING CYTOTOXIC CALCIUM OVERLOAD AND LIPID PEROXIDATION; ANTIEPILEPTIC, ANTIISCHEMIC, AND ANTIEDEMIC AGENTS; BRAIN, NERVOUS SYSTEM, AND CARDIOVASCULAR DISORDERS SUNTORY LIMITED (JP) 2002-06-18 US disclosed
US-20020006947-A1 Aryl substituted pyrazoles, triazoles, and tetrazoles, and the use thereof PURDUE PHARMA L.P. 2002-01-17 US disclosed
EP-1138678-A2 Process for making N-((4-phenyl) methylphenyl) piperazines SUNTORY LIMITED (JP) 2001-10-04 EP disclosed
WO-2001072714-A2 ARYL SUBSTITUTED PYRAZOLES, TRIAZOLES AND TETRAZOLES AS SODIUM CHANNEL BLOCKER EURO-CELTIQUE S.A. (LU) 2001-10-04 WO disclosed
WO-2001057008-A1 2-BENZOTHIAZOLYL UREA DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS ABBOTT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG & COMPANY KOMMANDITGESELLSCHAFT (DE) 2001-08-09 WO disclosed
EP-0784612-A1 UREA DERIVATIVES AND THEIR USE AS ACAT-INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1997-07-23 EP disclosed
EP-0353032-B1 1,5-BENZOTHIAZEPINE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF CARDIOVASCULAR DISORDERS Sankyo Company Limited (JP) 1992-02-26 EP disclosed
EP-0353032-A1 1,5-benzothiazepine derivatives, their preparation and their use in the treatment of cardiovascular disorders Sankyo Company Limited (JP) 1990-01-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250382273-A1 BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS BBOX1, NDUFB6, NDUFB5 ALDH1A1 108/4885TDP1 3666/4885CYP3A4 343/4885
US-20050182050-A1 Therapeutic heterocyclic compounds HTR1B, HTR1D, HTR1A ALDH1A1 517/4885TDP1 421/4885CYP3A4 319/4885
US-12331040-B2 Substituted benzofuranyl and benzoxazolyl compounds and uses thereof BCL6, MALT1, BTK ALDH1A1 503/4885TDP1 4056/4885CYP3A4 217/4885
US-20030013708-A1 Therapeutic heterocyclic compounds HTR1A, HTR1D, HTR1B ALDH1A1 399/4885TDP1 400/4885CYP3A4 252/4885
US-20020006947-A1 Aryl substituted pyrazoles, triazoles, and tetrazoles, and the use thereof GRIK5, CACNA1I, SOD1 ALDH1A1 431/4885TDP1 228/4885CYP3A4 587/4885
US-12617795-B2 Substituted 6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidines, 5,7-dihydrofuro[3,4-d]pyrimidines, and pyrido[2,3-d]pyrimidines as KCC2 modulators KCNC1, TRPC6, KCNH2 ALDH1A1 1204/4885TDP1 3056/4885CYP3A4 1114/4885
US-20260085064-A1 SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF BCL6, MALT1, BCL6B ALDH1A1 1202/4885TDP1 960/4885CYP3A4 422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.